Cantor Fitzgerald Estimates CATX FY2024 Earnings

Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Analysts at Cantor Fitzgerald issued their FY2024 earnings estimates for Perspective Therapeutics in a report issued on Tuesday, March 4th. Cantor Fitzgerald analyst L. Watsek forecasts that the company will post earnings per share of ($0.90) for the year. Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Perspective Therapeutics' current full-year earnings is ($0.88) per share. Cantor Fitzgerald also issued estimates for Perspective Therapeutics' FY2025 earnings at ($1.09) EPS.

A number of other brokerages have also recently commented on CATX. Royal Bank of Canada restated an "outperform" rating and set a $16.00 price target on shares of Perspective Therapeutics in a research note on Tuesday, January 14th. Wedbush reaffirmed an "outperform" rating and issued a $11.00 price target on shares of Perspective Therapeutics in a report on Friday, January 24th. Bank of America cut Perspective Therapeutics from a "buy" rating to a "neutral" rating and reduced their price target for the company from $24.00 to $5.00 in a research report on Monday, November 25th. Scotiabank began coverage on Perspective Therapeutics in a report on Friday. They set a "sector outperform" rating and a $15.00 price objective on the stock. Finally, Lifesci Capital upgraded Perspective Therapeutics to a "strong-buy" rating in a research note on Thursday. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Buy" and an average price target of $15.13.

Remove Ads

Perspective Therapeutics Price Performance

NYSE:CATX traded down $0.07 on Thursday, reaching $2.54. 355,384 shares of the company's stock were exchanged, compared to its average volume of 832,323. The stock has a fifty day simple moving average of $3.21 and a 200-day simple moving average of $7.66. Perspective Therapeutics has a 52 week low of $2.32 and a 52 week high of $19.05.

Institutional Trading of Perspective Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Creative Planning increased its position in shares of Perspective Therapeutics by 135.0% in the third quarter. Creative Planning now owns 41,175 shares of the company's stock worth $550,000 after purchasing an additional 23,655 shares during the last quarter. US Bancorp DE grew its stake in Perspective Therapeutics by 142.7% in the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company's stock worth $88,000 after buying an additional 3,866 shares in the last quarter. Los Angeles Capital Management LLC bought a new position in shares of Perspective Therapeutics in the 3rd quarter worth $153,000. WealthPlan Investment Management LLC purchased a new stake in shares of Perspective Therapeutics during the 3rd quarter valued at $4,530,000. Finally, Victory Capital Management Inc. raised its position in shares of Perspective Therapeutics by 328.7% during the 3rd quarter. Victory Capital Management Inc. now owns 50,460 shares of the company's stock valued at $674,000 after buying an additional 38,690 shares in the last quarter. Hedge funds and other institutional investors own 54.66% of the company's stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.